The GLP-1 medications provided under this program include: Wegovy (semaglutide) Saxenda (liraglutide) Mounjaro (tirzepatide) Shortages and Availability Due to high demand, the FDA has reported shortages for these medications, with expected limited availability through parts of 2024
Food and Drug Administration in July, the DEA said Thursday that Takeda Pharmaceuticals may now increase its production limit by 24%
Although they demonstrated that GLP1RAs safely and effectively reduce HbA1c levels in transplant recipients, they were limited by small sample size, short duration, or focused mainly on kidney-transplant recipients ( To evaluate the effects of GLP1RAs on glycemic control and cardiometabolic risk factors, and the occurrence of adverse events, we followed a population of liver-transplanted individuals with post-transplant diabetes mellitus who were treated for 18 months
Group 1 (the control group
Arrived very fast and very effective
These treatments address both high blood sugar and excess weight, which are often co-existing conditions